Sexually transmitted diseases in women

References

• Gunn RA, Rolfs RT, Greenspan JR, et al. The changing paradigm of sexually transmitted disease control in the era of managed health care. JAMA 1998s; 279(9):680–4
   Google Scholar
• Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press, 1996
   Google Scholar
• Hessol NA, Priddy FH, Bolan G, et al. Management of pelvic inflammatory disease by primary care physicians: a comparison with Centers for Disease Control and Prevention guidelines. Sex Transm Dis 1996; 23(2):157–63
   Google Scholar
• Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1998; 47(RR-1):1–111
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Summary of notifiable diseases. United States, 1997. MMWR 1997; 46(54): 73
   Google Scholar
• Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999; 179(Suppl 2):S380–3
   Google Scholar
• Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Mardh PA, et al, eds. Sexually transmitted diseases. 3d ed. New York: McGraw-Hill, 1999:407–19
   Google Scholar
• Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998; 280(6):521–6
   PubMed Web of Science ®Google Scholar
• Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997; 10(1): 160–84
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Howell MR, Pare B, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998; 339(11):739–44
   PubMed Web of Science ®Google Scholar
• Lee HH, Chernesky MA, Schachter J, et al. Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. Lancet 1995; 345(8944):213–6
   Google Scholar
• Howell MR, Quinn TC, Brathwaite W, et al. Screening women for Chlamydia trachomatis in family planning clinics: the cost effectiveness of DNA amplification assays. Sex Transm Dis 1998; 25(2):108–17
   Google Scholar
• Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics: a cost-effectiveness analysis of three strategies. Ann Intern Med 1998;128(4):277–84
   Google Scholar
• Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74:613–34
   PubMed Web of Science ®Google Scholar
• Wehbeh HA, Ruggeirio RM, Shahem S, et al. Single-dose azithromycin for Chlamydia in pregnant women. J Reprod Med 1998; 43(6):509–14
   PubMed Web of Science ®Google Scholar
• Adair CD, Gunter M, Stovall TG, et al. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998; 91(2):165–8
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex virus. Clin Infect Dis 1998; 26:541–55
   PubMed Web of Science ®Google Scholar
• Oxman MN. Genital herpes. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. 2d ed. Philadelphia: Saunders, 1998:986–1007
   Google Scholar
• Green J, Kocsis A. Psychological factors in recurrent genital herpes. Genitourin Med 1997; 73(4):253–6
   Google Scholar
• Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the Unites States, 1976 to 1994. N Engl J Med 1997; 337(16): 1105–11
   PubMed Web of Science ®Google Scholar
• Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 330:770–5
   Google Scholar
• Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV seropositive women. Ann Intern Med 1995; 123(11):845–7
   Google Scholar
• Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327(11): 782–9
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Washington, DC: ACOG, 1998; ACOG Educational Bulletin No. 245: 7
   Google Scholar
• Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124(2 Pt 1):8–15
   Google Scholar
• Reitano M, Tyring S, Lang W, et al. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998; 178:603–10
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes. JAMA 1998; 280(10):887–92
   PubMedGoogle Scholar
• Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984; 251(16): 2103–7
   PubMed Web of Science ®Google Scholar
• Kroon S. Genital herpes—when and how to treat. Semin Dermatol 1990; 9(2): 133–40
   Google Scholar
• Mertz GJ, Eron L, Kaufman R, et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988; 85(2A):14–9
   Google Scholar
• Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 1995;122(12):889–98 [Erratum: Ann Intern Med 1995; 123(5):395]
   PubMed Web of Science ®Google Scholar